Universal reference book for medicines
Name of the preparation: PERMIXON В®

Active substance: Serenoa repens

Type: Phytomedication used for functional disorders of urination associated with benign prostatic hyperplasia

Composition, form of production and packaging
Capsules of
light green color, size 1;
the contents of the capsules are greenish pasty substance with a characteristic odor.
1 caps.

lipidosterol extract of Serenoa repens 160 mg

Excipients: polyethylene glycol (macrogol 10 000), titanium dioxide, indigocarmine, iron oxide yellow, gelatin.

15 pcs.
- packings cellular planimetric (2) - packs cardboard.

The description of the drug was approved by the manufacturer for the 2006 print edition.


Lipidosterol extract of palm fruits Serenoa repens.
Has antiandrogenic, anti-inflammatory, anti-edematous and antiproliferative effects, selectively manifested at the level of the prostate gland. In this case, the drug does not affect the level of sex hormones in the blood plasma, does not affect the potency and libido and does not change the level of prostate-specific antigen in the blood plasma.
The mechanism of local antiandrogenic action is due to the inhibition of the synthesis of dihydrotestosterone (due to the inhibition of the enzyme 5-alpha-reductase I and II types) and its fixation to the cytosolic receptors, which prevents the penetration of the hormone into the nucleus.
As a result, protein synthesis is reduced.
The mechanism of local anti-inflammatory action is due to the fact that lipidosterol extract of Serenoa repens inhibits the activity of phospholipase A2 and the release of arachidonic acid, thereby reducing the synthesis of prostaglandins and leukotrienes, which are inflammatory mediators.
Permixon during the first weeks of therapy reduces capillary permeability and vascular stasis, reduces swelling and inflammation in the prostate, eliminates the compression of the neck of the bladder and urinary canal, improving the urodynamics.
The local antiproliferative effect of the drug is manifested by a decrease in the activity of growth factors (primarily epidermal and fibroblastic) and the acceleration of apoptosis of prostate cells, which is reflected in inhibition of growth and a subsequent decrease in the volume of the prostate gland.

Thus, the drug Permixon contributes, on the one hand, to a decrease in the severity of the pathological symptoms of benign prostatic hyperplasia (dysuria, pollakiuria, nocturia, pain and tension when urinating, incomplete emptying of the bladder), increased volume and strength of urination.
On the other hand, against the background of the use of the drug, further growth and increase in the volume of the prostate gland is somewhat slowed down.

Data on the pharmacokinetics of the Permixon preparation are not available.


- benign hyperplasia (adenoma) of the prostate of the I and II stages.


The optimal treatment regimen is set individually, based on the diagnostic examination.

The daily dose is 320 mg.
It is recommended to take 160 mg (2 tablets or 1 caps.) 2 times / day or 320 mg (4 tablets or 2 caps.) In 1 dose.
The duration of treatment is at least 3 months.
If necessary, repeated courses of therapy are possible.

In some cases: nausea, heartburn, gastralgia (usually occurring when taking the drug during meals).


- Hypersensitivity to the drug.


Permixone is recommended for taking with meals.


At present, no cases of an overdose of Permixon were reported.

If you accidentally ingest a large amount of the drug, you should wash the stomach.


There was no evidence of Permixon antagonism and drugs from the groups most commonly used in the treatment of this disease: antibiotics, uroseptics and anti-inflammatory drugs.


The drug is released by prescription.


The drug should be stored out of the reach of children at a temperature of no higher than 25 В° C.
Shelf life of the tablets is 5 years. Shelf life of capsules is 3 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!